News & Events

Ordinary General Meeting of Shareholders of Probiodrug AG

All proposed resolutions approved with large majority   HALLE (SAALE), Germany, 14 June 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions […]

Probiodrug announces encouraging results of the Phase 2a SAPHIR Study

HALLE (SAALE), Germany, 11 June 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announced […]

Probiodrug to present and attend at International Conferences in June 2017

HALLE (SAALE), Germany, 30 May 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Probiodrug AG Announces Acceptance of PQ912 Pharmacology Paper by Peer Reviewed Journal

HALLE (SAALE), Germany, 16 May 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]

Probiodrug AG reports First Quarter 2017 Business Update

HALLE (SAALE), Germany, 12 May 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]

Probiodrug AG to Publish its First Quarter 2017 Business Update on 12 May 2017

HALLE (SAALE), Germany, 5 May 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its […]

Probiodrug AG to hold its Ordinary General Meeting of Shareholders on 13 June 2017

HALLE (SAALE), Germany, 02 May 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), has the honour […]

Probiodrug to attend an present at International Conferences in May 2017

HALLE (SAALE), Germany, 25 April 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Probiodrug to present at Huntington’s Disease Therapeutics Conference

The Glutaminyl Cyclase (QC) inhibitor PQ912 demonstrates beneficial effects in a preclinical Huntington´s disease model   HALLE (SAALE), Germany, 10 April 2017 – Probiodrug AG (Euronext […]